Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Bill Gates' nuclear power venture, TerraPower Isotopes, has become the first to boost production of a radioactive substance that has shown new promise in the fight against cancer, called actinium ...

Actinium Pharmaceuticals ( (ATNM)) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors. Actinium Pharmaceuticals, Inc. is a ...